Pharmaceutical companies at ASCO 2027
Jun 4–8, 2027 Chicago, IL ~44k attendees Website
31 pharmaceutical companies are at ASCO 2027 — 31 with a booth in the exhibit hall. 31 of them have their own page in this guide. As of Oct 8, 2026.
Showing 1–20 of 31 organizations
| Organization | ASCO 2027 Attendance |
|---|---|
AbbVie North Chicago, IL | |
Global drugmaker whose cancer medicines include venetoclax and ibrutinib for blood cancers and the ADC mirvetuximab soravtansine for ovarian cancer. | Booth Exhibiting at Booth 27033 |
Amgen Thousand Oaks, CA | |
Biotechnology drugmaker with cancer medicines for lung, blood and colorectal cancers, including targeted therapies and bispecific T-cell engagers. | Booth Exhibiting at Booth 22025 |
Astellas Tokyo, Japan | |
Japanese drugmaker with cancer medicines including enzalutamide for prostate cancer, enfortumab vedotin for bladder cancer and zolbetuximab for gastric cancer. | Booth Exhibiting at Booth 15117 |
AstraZeneca Cambridge, UK | |
Global drugmaker with cancer medicines across lung, breast, blood and other cancers, including targeted therapies, immunotherapy and ADCs. | Booth Exhibiting at Booth 19029 |
Bayer Leverkusen, Germany | |
Global drugmaker whose cancer medicines include darolutamide and radium-223 for prostate cancer and regorafenib for colorectal and liver cancers. | Booth Exhibiting at Booth 13059 |
BeOne Medicines Basel, Switzerland | |
Global oncology company, formerly BeiGene, marketing zanubrutinib for blood cancers and the PD-1 antibody tislelizumab. | Booth Exhibiting at Booth 24021, 24033 |
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned German drugmaker whose oncology work centers on lung cancer, including the HER2 inhibitor zongertinib, plus other solid tumors. | Booth Exhibiting at Booth 27109 |
Bristol Myers Squibb Lawrence Township, NJ | |
Global drugmaker with immuno-oncology medicines such as nivolumab, plus myeloma, lymphoma and other blood cancer drugs and CAR-T cell therapies. | Booth Exhibiting at Booth 15093 |
Chugai Pharmaceutical Chuo-ku, Japan | |
Japanese drugmaker in the Roche group, known for antibody engineering; its cancer medicines include alectinib for ALK-positive lung cancer. | Booth Exhibiting at Booth 10072 |
Daiichi Sankyo Tokyo, Japan | |
Japanese drugmaker known for antibody-drug conjugates, including trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, for breast, lung and gastric cancers. | Booth Exhibiting at Booth 27073 |
Dr. Reddy's Laboratories Hyderabad, India | |
Indian drugmaker of generic medicines, biosimilars and specialty products, with oncology among its major therapy areas. | Booth Exhibiting at Booth 10102 |
Eisai Tokyo, Japan | |
Japanese drugmaker whose cancer medicines include lenvatinib, used in thyroid, liver, kidney and endometrial cancers, and eribulin for breast cancer. | Booth Exhibiting at Booth 19093 |
Eli Lilly Indianapolis, IN | |
Global drugmaker whose cancer medicines include abemaciclib for breast cancer, selpercatinib for RET-driven cancers and pirtobrutinib for blood cancers. | Booth Exhibiting at Booth 19079 |
EMD Serono (Merck KGaA) Boston, MA | |
Healthcare business of Germany's Merck KGaA, with EMD Serono's cancer medicines for colorectal, bladder and lung cancer and SpringWorks' rare tumor drugs. | Booth Exhibiting at Booth 23093 |
Genentech South San Francisco, CA | |
Roche company and biotechnology drugmaker with cancer medicines for breast, lung and blood cancers, including atezolizumab and bispecific antibodies. | Booth Exhibiting at Booth 19001 |
Gilead and Kite Foster City, CA | |
Gilead and its cell therapy company Kite, offering the ADC sacituzumab govitecan for breast cancer and CAR-T therapies for lymphoma and leukemia. | Booth Exhibiting at Booth 23001 |
Glenmark Pharmaceuticals Mumbai, India | |
Indian maker of branded and generic medicines sold in 80+ countries; its Ichnos Glenmark Innovation arm develops multispecific antibodies for myeloma. | Booth Exhibiting at Booth 34142, 34143 · Ichnos Glenmark Innovation (IGI) |
GSK London, UK | |
Global drugmaker with cancer medicines for gynecologic and blood cancers, including the PD-1 antibody dostarlimab and myeloma treatments. | Booth Exhibiting at Booth 19059 |
Ipsen Boulogne-Billancourt, France | |
French specialty drugmaker whose cancer medicines include irinotecan liposome (Onivyde) for pancreatic cancer and treatments for neuroendocrine tumors and prostate cancer. | Booth Exhibiting at Booth 11058 |
Jazz Pharmaceuticals Dublin, Ireland | |
Rare disease and oncology drugmaker with medicines for leukemia, small cell lung cancer and HER2-positive biliary tract cancer. | Booth Exhibiting at Booth 34095 |
Instantly find 20 buyers from pharmaceutical companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASCO 2027 by
Organization type
Focus
- Clinical trials 58
- Biomarkers and genomics 44
- AI and data 38
- Blood cancers 36
- Lung cancer 28
- Genitourinary cancers 24
- Gastrointestinal cancers 21
- Breast cancer 18
- Immunotherapy 17
- Imaging and radiation 17
- Patient support and survivorship 14
- Antibody-drug conjugates 9
- Cell and gene therapy 8
- Melanoma and skin cancers 7
- Gynecologic cancers 6
Exhibit hall
Everyone
Not affiliated with the American Society of Clinical Oncology. Organization details are derived from ASCO’s published exhibitor list and each exhibitor’s own profile and website. Submit a correction